Raymond James upgraded shares of Medexus Pharmaceuticals (TSE:MDP – Free Report) from an outperform rating to a strong-buy rating in a report issued on Wednesday morning,BayStreet.CA reports. The firm currently has C$4.00 target price on the stock.
A number of other brokerages also recently issued reports on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price target on shares of Medexus Pharmaceuticals and gave the stock a “speculative buy” rating in a research report on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Strong Buy” and an average price target of C$5.25.
View Our Latest Stock Analysis on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Up 4.0 %
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Articles
- Five stocks we like better than Medexus Pharmaceuticals
- 3 Dividend Kings To Consider
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Short Selling: How to Short a Stock
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.